Inventor

Irving L. Weissman

Inventor

Stanford, CA, US

Overview

1988–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 103 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes21%

C07KPeptides19%

C12NMicroorganisms or enzymes17%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%

G01NInvestigating or analysing materials by determining their chemical or physical properties13%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms9%

Y02ATechnologies for adaptation to climate change3%

A01KAnimal husbandry1%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%

A61LMethods or apparatus for sterilising materials or objects in general1%

PatentTitleYear

11,130,813Treatment of cancer with dual targeting of CD47 and EGFR2021 11,104,731Compositions for achieving therapeutically effective doses of anti-CD47 agents2021 11,083,755Factors and cells that provide for induction of bone, bone marrow, and cartilage2021 11,078,272Treatment of pediatric brain tumors with targeting of CD47 pathway2021 11,072,655Markers of acute myeloid leukemia stem cells2021 11,046,763Targeted therapy for small cell lung cancer2021 11,014,985Humanized and chimeric monoclonal antibodies to CD472021 10,995,152Modified immunoglobulin hinge regions to reduce hemagglutination2021 10,942,185Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor2021 10,934,355Methods and compositions for the prevention and treatment of surgical adhesions2021 10,934,331Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells2021 10,894,831Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist2021 10,889,649Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance2021 10,822,411Targeting aneurysm disease by modulating phagocytosis pathways2020 10,800,830High affinity PD-1 agents and methods of use2020 10,787,640Producing mesodermal cell types and methods of using the same2020 10,780,117Macrophages eat cancer cells using their own calreticulin as a guide2020 10,781,256Anti SIRP-a antibodies and bi-specific macrophage enhancing antibodies2020 10,723,803CD47 targeted therapies for the treatment of infectious disease2020 10,662,242Markers of acute myeloid leukemia stem cells2020 10,645,912Method for producing chimeric animal2020 10,640,561Methods for manipulating phagocytosis mediated by CD472020 10,618,976SIRP-a agonist antibody2020 10,611,842Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPa antibody therapy2020 10,543,235Pericytes are intermediate progenitors for epicardial derived coronary artery smooth muscle2020 10,406,179Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling2019 10,386,361Long term hematopoietic stem cell specific reporter mouse and uses thereof2019 10,358,472High affinity CD47 analogs2019 10,344,094Treatment of cancer with dual targeting of CD47 and EGFR2019 10,329,354Modulation of efferocytosis pathways for treatment of atherosclerotic disease2019 10,316,094Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance2019 10,301,387Methods for achieving therapeutically effective doses of anti-CD47 agents2019 10,184,004CD47 targeted therapies for the treatment of infectious disease2019 10,081,680Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies2018 10,072,091Selective immunodepletion of endogenous stem cell niche for engraftment2018 10,064,925Use of anti-CD47 agents to enhance immunization2018 9,957,576Methods for determining responsiveness to an anti-CD47 agent2018 9,945,870Methods for determining responsiveness to an anti-CD47 agent2018 9,944,911High affinity Sirp-alpha reagents and methods of using2018 9,796,781'Markers of acute myeloid leukemia stem cells'2017 9,771,428'CD47 targeted therapies for the treatment of infectious disease'2017 9,765,143'Methods for manipulating phagocytosis mediated by CD47'2017 9,623,079'Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer'2017 9,624,305'Methods of manipulating phagocytosis mediated by CD47'2017 9,611,329'Methods of manipulating phagocytosis mediated by CD47'2017 9,605,076'Methods of manipulating phagocytosis mediated by CD47'2017 9,562,087'High affinity PD-1 agents and methods of use'2017 9,546,206'High affinity PD-1 agents and methods of use'2017 9,493,575'Methods for manipulating phagocytosis mediated by CD47'2016 9,399,682'Methods for manipulating phagocytosis mediated by CD47'2016 9,382,320'Humanized and chimeric monoclonal antibodies to CD47'2016 9,193,955'Markers of acute myeloid leukemia stem cells'2015 9,175,079'Depletion of teratoma-forming pluripotent stem cells'2015 9,151,760'Isolation and use of melanoma cancer stem cells'2015 9,045,734'Isolation and characterization of progenitor cells from mesothelium'2015 9,017,675'Humanized and chimeric monoclonal antibodies to CD47'2015 8,765,390'Identification and isolation of squamous carcinoma stem cells'2014 8,758,750'Synergistic anti-CD47 therapy for hematologic cancers'2014 8,709,429'Markers of acute myeloid leukemia stem cells'2014 8,562,997'Methods of treating acute myeloid leukemia by blocking CD47'2013 8,361,736'Ex vivo methods for targeting or depleting acute myeloid leukemia cancer stem cells'2013 8,232,071'In vitro depletion of acute myeloid leukemia stem cells'2012 8,153,388'Methods for phenotyping of leukemias'2012 7,816,088'Identification, isolation and elimination of cancer stem cells'2010 7,803,783'Use of WNT inhibitors to augment therapeutic index of chemotherapy'2010 7,781,179'Identification and isolation of transitional cell carcinoma stem cells'2010 7,767,410'Identification and isolation of acute myeloid leukemia stem cells'2010 7,749,754'Isolation and characterization of muscle regenerating cells'2010 7,641,897'Feeder layer and serum independent embryonic stem cells'2010 7,622,255'Methods of identifying and isolating stem cells and cancer stem cells'2009 7,618,654'Mammalian myeloid progenitor cell subsets'2009 7,592,174'Isolation of mesenchymal stem cells'2009 7,514,229'Methods for diagnosing and evaluating treatment of blood disorders'2009 7,494,807'Mammalian megakaryocyte progenitor cell'2009 7,300,760'Mammalian myeloid progenitor cell subsets'2007 7,297,329'Mammalian common lymphoid progenitor cell'2007 7,217,568'Methods of identifying and isolating stem cells and cancer stem cells'2007 7,217,565'Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations'2007 7,153,686'Compositions of enriched central nervous system stem cell and progenitor cell populations'2006 7,105,150'In vivo screening methods using enriched neural stem cells'2006 7,037,719'Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations'2006 6,991,939'Optical array device and methods of use thereof for screening, analysis and manipulation of particles'2006 6,908,763'Mammalian common lymphoid progenitor cell'2005 6,761,883'Mammalian myeloid progenitor cell subsets'2004 6,468,794'Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations'2002 6,465,247'Mammalian myeloid progenitor cell subsets'2002 6,465,249'Use of -catenin in the expansion of stem and progenitor cells'2002 5,928,638'Methods for gene transfer'1999 5,914,108'Human hematopoietic stem cell'1999 5,821,108'Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker'1998 5,763,197'Human hematopoietic stem cell'1998 5,750,397'Human hematopoietic stem cell'1998 5,716,827'Human hematopoietic stem cell'1998 5,643,741'Identification and isolation of human hematopoietic stem cells'1997 5,614,397'Method and compositions for modulating lifespan of hematolymphoid cells'1997 5,447,852'DNA encoding cyclophilin C, and recombinant methods employing it'1995 5,362,629'Detection of immunosuppressants'1994 5,213,977'Serine protease from cytotoxic killer cells'1993 5,087,570'Homogeneous mammalian hematopoietic stem cell composition'1992 5,061,620'Human hematopoietic stem cell'1991 4,973,555'Human serine protease gene'1990 4,886,743'Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof'1989 4,786,590'Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis'1988

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1988–2021Patents assigned to UNIV LELAND STANFORD JUNIOR (88)· patent assignee history

1988–2021Based in Stanford, CA, US· patent location history

1991–1999Patents assigned to SYSTEMIX INC (7)· patent assignee history

1991–1999Based in Palo Alto, CA, US· patent location history

1992–2015Patents assigned to WEISSMAN IRVING L (9)· patent assignee history

1997–2010Based in Redwood City, CA, US· patent location history

2006–2007Patents assigned to STEMCELLS CALIFORNIA INC (4)· patent assignee history

2013–2014Patents assigned to MAJETI RAVINDRA (3)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV LELAND STANFORD JUNIOR	88	1988–2021
WEISSMAN IRVING Lself	9	1992–2015
SYSTEMIX INC	7	1991–1999
STEMCELLS CALIFORNIA INC	4	2006–2007
MAJETI RAVINDRA	3	2013–2014

Locations

Location	Patents	Span
Stanford, California, US	76	1988–2021
Redwood City, California, US	20	1997–2010
Palo Alto, California, US	7	1991–1999